What was the merger consideration for Illumina's acquisition of Grail?
As previously disclosed, the merger consideration for Illumina's acquisition of GRAIL included cash and shares of Illumina common stock, as well as contingent value rights (CVRs) or additional shares of Illumina common stock.
What does the Illumina-Grail deal mean for the cancer testing company?
[Read more...] Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering.
Is Illumina the perfect stock for long-term growth?
Still, the demand for Illumina’s next-generation sequencing tools are poised to surge tremendously, making the shares very attractive for longer-term growth investors. Meanwhile, after researching the issue of Illumina’s controversial acquisition of Grail, I think that there’s an 80%-90% chance that the deal will be approved.
What is the cash consideration for Illumina stock?
GRAIL stockholders, including Illumina, are entitled to cash consideration of approximately $3.5 billion or, excluding Illumina, approximately $3.1 billion. We are also spending approximately $0.4 billion in cash to cover the tax withholding requirements from net settling shares of Illumina common stock issuable to GRAIL employees.
See more
Can you buy stock in Illumina?
Illumina common stock can be bought or sold through a stockbroker, bank or financial institution that offers brokerage services.
How much does it cost to buy stock in Illumina?
During the day the price has varied from a low of $200.27 to a high of $207.97. The latest price was $207.00 (25 minute delay). Illumina is listed on the NASDAQ and employs 9,800 staff....Illumina shares at a glance.Open$201.16High$207.97Low$200.27Close$207.00Previous close$200.664 more rows
Does Illumina pay a dividend?
ILMN Illumina, Inc. ILMN does not currently pay a dividend.
Is Illumina a publicly traded company?
Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. The company went public at $16 per share on July 28, 2000.
Is Illumina a good investment?
Illumina is a good long-term investment since its projects and research will take time to realize returns when its products and patents make their way into the market. Speculators should avoid the stock as it tends to exhibit short-term fluctuation.
Is Grail a public company?
Grail, the company on a quest to spot cancers early with a simple blood test, is finally going public after raising nearly $2 billion in funding for its research since 2016.
Who owns Illumina?
Francis deSouzaIllumina, Inc.TypePublicKey peopleFrancis deSouza (President & CEO) John W. Thompson ( Board Chair) Sam Samad (CFO)ProductsNovaSeq 6000, HiSeq X, HiSeq 4000, MiSeq, MiSeqDx, MiniSeq, iSeq 100, NextSeq 550, NextSeq 550Dx, iScanRevenueUS$4.53 billion (2021)Operating incomeUS$−0.12 billion (2021)12 more rows
Why is Illumina stock falling?
Shares of Illumina were falling sharply Friday after the gene-sequencing supplier said that Sam Samad would be departing as its chief financial officer. Samad will leave Illumina (ticker: ILMN) on July 8, after serving as CFO for more than five years, the company said in a news release.
Who are Illumina's competitors?
Illumina's top competitors include Affymetrix, Qiagen, Luminex, BGI Genomics, Thermo Fisher Scientific, Bruker and Natera. Illumina is a company that develops, manufactures, and markets sequencing- and array-based integrated systems for genetic and genomic analysis.
Does Roche own Illumina?
“We are pleased that Roche has decided not to extend its inadequate offer to acquire Illumina and that we can now return our full focus to growing our business, making the most of the expanding opportunities in our space, and delivering superior results for our customers and stockholders,” said Illumina CEO Jay Flatley ...
Why is Illumina stock falling?
Shares of Illumina were falling sharply Friday after the gene-sequencing supplier said that Sam Samad would be departing as its chief financial officer. Samad will leave Illumina (ticker: ILMN) on July 8, after serving as CFO for more than five years, the company said in a news release.
Should I sell ILMN stock?
There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Illumina stock.
Who bought Grail?
Illumina announced the $8 billion cash-and-stock deal for startup Grail last September, buying out investors including Amazon founder Jeff Bezos, to regain control of a company it spun out five years ago. Reuters • 4 days ago.
What is the Grail biotech?
Five years ago, Illumina (NASDAQ: ILMN) created Grail, a liquid biopsy biotech that hopes to detect as many as 50 types of cancers with a single blood draw from patients . Grail was all set for its initial public offering when Illumina made an $8 billion offer to reacquire the company.
Why is Illumina probing the deal?
European officials are probing the deal because of concerns it "may reduce competition and innovation in the emerging market for the development and c.
About Illumina
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Headlines
Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?
Illumina (NASDAQ:ILMN) Frequently Asked Questions
10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Illumina stock.
Illumina Stock Dives On Grail Takeover
The saga to acquire Grail has been riddled with drama. Illumina founded Grail in 2016 and soon after spun it off into an independent company. Grail makes a variety of tests to detect cancer in a patient's blood. Last year, Illumina announced its plan to buy Grail for roughly $8 billion.
Analyst Remains Bullish On Deal
Canaccord's Mikson remained bullish on Illumina stock and the Grail deal.
How much of Illumina is owned by GRAIL?
Illumina stockholders are expected to own approximately 93 percent of the combined company, while GRAIL stockholders will own approximately 7 percent . The transaction is expected to add to to Illumina revenue starting in 2021.
Who bought GRAIL?
(RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock.
Is GRAIL a NGS?
It will also help transform cancer care using genomics and Illumina's Next-Generation Sequencing (NGS) platform. GRAIL comes back into the Illumina fold after it was spun out as a standalone company in January 2017. GRAIL was founded by Illumina in 2016 and is now backed by Amazon founder Jeff Bezos and billionaire Bill Gates.
